Onycho Pharma has acquired rights for Amycot® in the USA and will conduct a clinical trial program to permit out-license of product for commercialisation as a prescription medicine.
Amycot® is a highly efficacious natural treatment to manage onychomycosis using a patented bioactive extract from the cyanobacteria strain Arthrospira maxima.
Our product is a addressing a a massively undertreated and rapidly growing market.
Early clinical data (>100 patients) for this new topical treatment suggest:
- Mycological and clinical cure rates >70%
- No adverse treatment related effects and simple topical administration
Company Details
- Employees
- 2
- Founded
- 2019
- Address
- 190 Clemenceau Avenue #06-01, Singapore,state/province 239924,singapore
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.onycho-pharma.com
- Keywords
- Pharmaceutical Manufacturing.
- HQ
- Singapore, State/Province
Onycho Pharma Questions
Onycho Pharma's website is http://www.onycho-pharma.com
Onycho Pharma's LinkedIn profile is https://sg.linkedin.com/company/onycho-pharma
Onycho Pharma has
2 employees.
View email and phone details for 2
employees at Onycho Pharma.
Onycho Pharma's industry is
Pharmaceutical Manufacturing
Onycho Pharma's top competitors are
Marinex Pharma,
Compai Pharma,
Osteopathy Health Care,
Nutrition Pathway,
Catalent,
J&l Pharma Services,
Xecta Technologies Llc,
Capsule Pharma Singapore,
Avc Pharma Pte Ltd,
Inspa.
Onycho Pharma's categories are Pharmaceutical Manufacturing
Onycho Pharma's founding year is 2019
